Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph C Presti

Showing results (61-70 of 118) with videos related to

Pageof 12
Sort By:
The Journal of Urology|November 7, 2006
Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?Nicholas J Fitzsimons, Joseph C Presti, Christopher J Kane, et al.
BJU International|March 21, 2009
Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomySagar R Shah, Stephen J Freedland, William J Aronson, et al.
The Prostate|September 22, 2012
Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH databaseMichael R Abern, William J Aronson, Martha K Terris, et al.
BJU International|November 17, 2009
Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) databaseDaniel M Moreira, Joseph C Presti, William J Aronson, et al.
The Prostate|August 6, 2010
Glycemic control and prostate cancer progression: results from the SEARCH databaseHoward S Kim, Joseph C Presti, William J Aronson, et al.
BJU International|June 25, 2009
Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database GroupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
European Urology|December 19, 2012
Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH databaseChristopher J Keto, William J Aronson, Martha K Terris, et al.
Urology|June 29, 2013
Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database groupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
Urology|December 15, 2010
Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database groupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
BJU International|November 19, 2011
Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH databaseChristopher J Keto, William J Aronson, Martha K Terris, et al.
Pageof 12

Showing results (61-70 of 118) with videos related to

Sort By:
Pageof 12
The Journal of Urology|November 7, 2006
Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?Nicholas J Fitzsimons, Joseph C Presti, Christopher J Kane, et al.
BJU International|March 21, 2009
Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomySagar R Shah, Stephen J Freedland, William J Aronson, et al.
The Prostate|September 22, 2012
Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH databaseMichael R Abern, William J Aronson, Martha K Terris, et al.
BJU International|November 17, 2009
Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) databaseDaniel M Moreira, Joseph C Presti, William J Aronson, et al.
The Prostate|August 6, 2010
Glycemic control and prostate cancer progression: results from the SEARCH databaseHoward S Kim, Joseph C Presti, William J Aronson, et al.
BJU International|June 25, 2009
Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database GroupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
European Urology|December 19, 2012
Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH databaseChristopher J Keto, William J Aronson, Martha K Terris, et al.
Urology|June 29, 2013
Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database groupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
Urology|December 15, 2010
Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database groupAnna E Teeter, Joseph C Presti, William J Aronson, et al.
BJU International|November 19, 2011
Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH databaseChristopher J Keto, William J Aronson, Martha K Terris, et al.
Pageof 12